Nebivolol: A review

John Cockcroft*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

51 Citations (Scopus)


Nebivolol is a vasodilating β-blocker, which can be distinguished from other β-blockers by its haemodynamic profile. It combines β-adrenergic blocking activity with a vasodilating effect mediated by the endothelial L-arginine nitric oxide (NO) pathway. The blood pressure lowering effect of nebivolol is linked to a reduction in peripheral resistance and an increase in stroke volume and preservation of cardiac output. The effects of nebivolol have been compared with other β-blockers and also with other classes of antihypertensive agents. In general, response rates to treatment are higher and the frequency and severity of adverse events are either comparable or lower with nebivolol. Endothelium-derived NO is important in the regulation of large arterial stiffness, which in turn is a major risk factor for cardiovascular disease. Therefore, antihypertensive drugs, such as nebivolol, that also improve endothelial function and decrease arterial stiffness, may contribute to a reduction in cardiovascular risk. 2004

Original languageEnglish
Pages (from-to)893-899
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Issue number4
Publication statusPublished - Apr 2004


  • Β-blocker
  • Arterial stiffness
  • Hypertension
  • Nebivolol
  • Nitric oxide


Dive into the research topics of 'Nebivolol: A review'. Together they form a unique fingerprint.

Cite this